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Progression of Coronary Artery Calcium and Incident Heart Failure:
The Multi-Ethnic Study of Atherosclerosis
Hooman Bakhshi, MD; Bharath Ambale-Venkatesh, PhD; Xiaoying Yang, MS; Mohammad R. Ostovaneh, MD, MPH; Colin O. Wu, PhD;
Matthew Budoff, MD; Hossein Bahrami, MD, MPH, PhD; Nathan D. Wong, PhD, MPH; David A. Bluemke, MD, PhD; Jo~ao A.C. Lima, MD
Background-—Although the association between coronary artery calcium (CAC) and future heart failure (HF) has been shown
previously, the value of CAC progression in the prediction of HF has not been investigated. In this study, we investigated the
association of CAC progression with subclinical left ventricular (LV) dysfunction and incident HF in the Multi-Ethnic Study of
Atherosclerosis.
Methods and Results-—The Multi-Ethnic Study of Atherosclerosis is a population-based study consisting of 6814 men and women
aged 45 to 84, free of overt cardiovascular disease at enrollment, who were recruited from 4 ethnicities. We included 5644 Multi-
Ethnic Study of Atherosclerosis participants who had baseline and follow-up cardiac computed tomography and were free of HF
and coronary heart disease before the second cardiac computed tomography. Mean (SD) age was 61.710.2 years and 47.2%
were male. The Cox proportional hazard models and multivariable linear regression models were deployed to determine the
association of CAC progression with incident HF and subclinical LV dysfunction, respectively. Over a median follow-up of 9.6
(interquartile range: 8.8–10.6) years, 182 participants developed incident HF. CAC progression of 10 units per year was associated
with 3% of increased risk of HF independent of overt coronary heart disease (P=0.008). In 2818 participants with available cardiac
magnetic resonance images, CAC progression was associated with increased LV end diastolic volume (b=0.16; P=0.03) and LV end
systolic volume (b=0.12; P=0.006) after excluding participants with any coronary heart disease.
Conclusions-—CAC progression was associated with incident HF and modestly increased LV end diastolic volume and LV end
systolic volume at follow-up exam independent of overt coronary heart disease. ( J Am Heart Assoc. 2017;6:e005253. DOI: 10.
1161/JAHA.116.005253.)
Key Words: cardiac computed tomography • cardiac magnetic resonance imaging • coronary artery calcium • coronary artery
calcium progression • heart failure
H eart failure (HF) is a disabling disease with high burdenon health care economy.1 It affects both men and
women with a lifetime risk of 20%.2 Secondary to a
combination of population aging and improvement in the
managements of acute cardiovascular diseases, incidence
and prevalence of HF have been increasing continuously in
the past decades.3 Approximately 5.7 million Americans
suffer from HF,1 and each year more than 550 000 new
cases of HF are diagnosed.4 The most common cause of HF in
the United States is coronary artery disease (CAD).5 CAD
plays its role in the pathophysiology of HF through different
mechanisms.6 In addition to clinically overt coronary heart
disease (CHD), hypoperfusion and endothelial dysfunction
may cause subclinical myocardial damage and dysfunction,
which eventually will progress to symptomatic HF.7 Myocar-
dial dysfunction in the subclinical phase is detectable by
cardiac imaging, including echocardiography and cardiac
magnetic resonance (CMR). Considering the progressive
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nature of HF and to implement effective risk modification
strategies, it is imperative to detect asymptomatic individuals
at risk to develop HF.8 Coronary artery calcium (CAC)
measurement by noncontrast cardiac computed tomography
is a reliable and accurate tool to detect subclinical
atherosclerosis and has a strong correlation with atheroscle-
rotic plaque burden.9 CAC score has incremental value over
traditional risk scoring systems for cardiovascular risk
stratification, especially in individuals who are classified as
intermediate risk.10 Serial measurement of CAC score has
been introduced as a tool to monitor the progression of
subclinical atherosclerosis.11 CAC progression has a good
predictive value for incident CHD and all-cause mortality.12,13
Although the association between CAC and incident HF has
been demonstrated in a few studies independent of CHD,14–17
the value of CAC progression in prediction of future HF has
not been previously evaluated. In this study, we investigate
CAC progression as a predictor of incident HF and subclinical
left ventricular (LV) dysfunction measured by CMR in a
population-based cohort.
Materials and Methods
The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospec-
tive, population-based cohort study including 4 racial/ethnic
groups (whites, blacks, Hispanics, and Chinese).The design of
MESA has been published in detail previously.18 Briefly,
between July 2000 and August 2002 (Exam 1), 6814 men
and women, aged 45 to 84 years and free of clinical
cardiovascular disease at enrollment, were recruited from 6
US field centers (Baltimore, MD; Chicago, IL; Forsyth County,
NC; Los Angeles County, CA; Northern Manhattan, NY; and St
Paul, MN). All participants gave written informed consents and
all study protocols were approved by the institutional review
boards of each participating field center. Baseline examination
(Exam 1) were followed by 4 more examinations with the
following timeline: Exam 2 (September 2002–February 2004);
Exam 3 (March 2004–September 2005); Exam 4 (September
2005–May 2007); and Exam 5 (April 2010–December 2011). In
this study, we included all MESA participants who had CAC
measured by cardiac computed tomography at baseline (Exam
1) and follow-up (Exam 2 or 3). There were 142 participants
who developed incident CHD, 58 who developed incident HF,
and 35 who developed both incident CHD and HF before their
second cardiac computed tomography and were excluded from
this analysis.
At Exam 1, standard questionnaires were used to obtain
demographic, medical, and family history, medication use,
smoking status, household income, and highest education
level. Smoking status was defined as never, former, or current
smoker. BMI was calculated as weight (kg) divided by the
square of height (m2). Resting blood pressure was measured 3
times using the Dinamap model Pro 100 automated oscillo-
metric sphygmomanometer (Critiko, Tampa, FL) in the upright
position and the mean of the last 2 measurements was
recorded. Fasting blood glucose as well as total and high-
density lipoprotein (HDL) cholesterol were measured in
serum. Participants were classified as normal and impaired
fasting glucose if fasting blood glucose was <100 mg/dL and
100 to 125 mg/dL respectively. Diabetes mellitus was
defined as fasting blood glucose ≥126 mg/dL or the use of
insulin or any other hypoglycemic medication. An ElecSys
2010 analyzer (Roche Diagnostics, Indianapolis, IN) was used
to measure N-Terminal prohormone of brain natriuretic
peptide (NT-proBNP). Electrocardiogram was utilized to mea-
sure resting hear rate.
The details of the acquisition method of cardiac computed
tomography in MESA has been published previously.12,19 For
each participant 2 consecutive scans were obtained over a
standard calcium phantom at both baseline and follow-up
exams. All images were transferred to a central computed
tomography reading center (Los Angeles Biomedical Research
Institute, Torrance, CA) and interpreted by an experienced
physician. CAC score was calculated using the method
introduced by Agatston et al. The mean of 2 scans at each
exam were used for data analysis after being adjusted
according to the calcium phantom. The acquisition method of
CMR images in MESA has been explained in detail in previous
publications.20,21 CMR was performed using 1.5 Tesla scan-
ners. In Exam 5, the steady-state free precession pulse
sequence was used to measure the parameters of cardiac
function and structure. All CMR images were analyzed by
blinded readers in a central magnetic resonance imaging
(MRI) reading center (Johns Hopkins Hospital, Baltimore, MD).
CMR images in Exam 5 were quantified using CIM software
(version 6.0; UniServices, Auckland, New Zealand). The
following CMR variables were used in our study: LV mass
(LVM); LV end diastolic volume (LVEDV); LV end systolic
volume (LVESV); stroke volume (SV); ejection fraction (EF);
and mass-to-volume ratio (MVR; MVR=LV mass/LVEDV). The
first 4 variables were indexed to body surface area. In 3
participants, the indexed parameters were not calculated
because of missing weight variable. In 1 participant, EF, SV,
and LVESV were missing.
Every 9 to 12 months, a telephone interviewer called each
participant to find about any interim hospital admissions,
cardiovascular outpatient diagnoses, and deaths. Inpatient
and outpatient medical records and information were received
successfully in 98% and 95%, respectively. CHD was
assessed as any of myocardial infarction, resuscitated cardiac
arrest, definite angina, probable angina (if followed by
revascularization), and CHD death. The end point for our
study was a combination of probable and definite HF. Both
types required clinical symptoms and signs of HF, such as
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shortness of breath or edema. HF was considered probable if
a physician made the diagnosis and the patient was receiving
medical treatment for HF. Definite HF required to meet at
least 1 of the following criteria: (1) pulmonary edema/
congestion in chest x-ray; (2) dilated or dysfunctional LV by
echocardiography or any ventriculography; or (3) any evidence
of LV diastolic dysfunction.
Statistical Analysis
Baseline characteristics are presented using meanSD or
numbers (%). CAC progression (continuous variable) was
calculated as follow-up CAC minus baseline CAC divided by
interscan period in years (annualized change in CAC). In
addition, progressors versus nonprogressores (categorical
variable) was defined using the method that was introduced
by Berry et al.22 A participant is considered as a progressor if
he or she has:
1. Baseline CAC=0 and follow-up CAC more than zero, or
2. 0 < baseline CAC ≤100 and annualized change in CAC
≥10, or
3. Baseline CAC >100 and annualized relative change in CAC
≥10% (annualized change in CAC divided by baseline CAC
multiplied by 100).
The Cox proportional hazards (CPH) model was used to
evaluate the association of CAC progression, either continu-
ous CAC progression or categorical CAC progression, and
time to incident HF in participants free of any CHD or HF
before the follow-up CAC measurement. Three separate
models were used for the analysis:
Model 1: CPH regression without adjusting covariates
other than CAC progression.
Model 2: CPH regression with covariate adjustment for
demographics and known risk factors of HF (Exam 1),
including age, sex, race, BMI, systolic blood pressure (SBP),
diastolic blood pressure (DBP), use of antihypertensive
medication, total cholesterol, HDL cholesterol, use of lipid-
lowering medication, diabetes mellitus, cigarette smoking
status, heart rate, creatinine, highest education level,
household income, and baseline CAC score. A sensitivity
analysis was done by comparing the results with and
without adjusting for baseline NT-proBNP. Participants with
any CHD and HF before second CAC measurement were
excluded.
Model 3: model 2 after excluding the participants with any
CHD before and after second CAC measurement. Sub-
groups analyses were done for participants with baseline
CAC=0 and participants with baseline CAC >0.
For the analysis of LV dysfunction, multivariable linear
regression models were used to assess the association of
CAC progression, either continuous or categorical CAC
progression, with each of the MRI parameters of LV function
and structure at Exam 5. The same exclusion criteria were
applied as in the CPH analysis. Two adjusted models were
constructed with the covariates that were used for CPH
analysis. Given that the distribution of CAC scores is skewed,
the baseline CAC score in the models was transformed by the
logarithmic transformation [ln (CAC+1)]. All statistical results
were computed using Stata statistical software (version 14.1;
StataCorp LP, College Station, TX). P value of less than 0.05
was considered significant.
Results
A total of 5644 MESA participants free of HF and CHD before
the second CAC measurement were included in this study.
The baseline characteristics of the study participants are
shown in Table 1. The mean (SD) interscan period (baseline
and follow-up) was 2.40.9 years. Baseline CAC was zero in
more than half of the cohort population (51.8%), and the
majority (84.1%) remained CAC free in the second measure-
ment. Of those with baseline CAC >0 to 100 and >100, 43.3%
and 66.9% showed progression based on the above-defined
basis for identifying progressors, respectively.
Over a median 9.6 (interquartile range [IQR], 8.8–10.6)
years of follow-up from the second CAC measurement (12.2
[IQR, 11.7–12.7] years from Exam 1), 182 participants
developed incident HF. Of those with HF, 83 participants
developed concomitant CHD. Using CAC progression as a
continuous variable, a longitudinal increase in CAC of
10 Agatston Units (AU) per year was associated with 2%
(P=0.012) of increased risk of HF independent of known risk
factors for HF and baseline CAC. This association remained
statistically significant after excluding the participants with
CHD (Table 2). The association between CAC progression as a
categorical variable and HF was not statistically significant in
adjusted models. Subgroups analysis were performed for
participants with baseline CAC=0 and CAC >0 separately
(Table 3). Any change in CAC from zero was associated with a
hazard ratio (HR) of 2.52 (P=0.003) independent of traditional
cardiovascular risk factors. In Figure, Kaplan–Meier curves of
cumulative events show higher cumulative incident of HF in
progressors compared to nonprogressors (Figure Panel A: full
cohort; Figure Panel B: baseline CAC=0; and Figure Panel C:
baseline CAC >0). A sensitivity analysis was done on a group
of 4664 participants with available baseline NT-proBNP to
investigate the effect of adjusting the CPH models for NT-
proBNP (Table S1). The magnitude and significance of the
associations remained largely unchanged.
Follow-up CMR images (Exam 5) were available for 2818
participants who were free of HF and CHD before the second
CAC measurement. MeanSD of the parameters of LV
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function and structure have been summarized in Table S2.
Compared to participants with baseline CAC >0, participants
with baseline CAC=0 showed higher EF and SV and lower LVM
and MVR at the follow-up exam.
Table 4 shows the association between CAC progression
and LV function and structure measured by CMR at Exam 5.
Longitudinal increase in CAC was associated with higher
LVESV (b=0.09; P<0.05) independent of traditional cardio-
vascular risk factors. This association remained statistically
significant after excluding the participants with any CHD. The
association between CAC progression and LVEDV became
statistically significant only after excluding participants with
any CHD (b=0.16; P=0.03). Progressors showed statistically
significant associations with increased LVESV (b=0.79;
P=0.034) and LVEDV (b=1.21; P<0.05). These associations
had reduced statistical significance level after excluding the
participants with any CHD. Subgroup analyses were done for
participants with baseline CAC=0 and CAC >0 (Tables S3 and
S4). In participants with baseline CAC=0, CAC progression
was associated with increased LVEDV, LVESV, and LVM in
Table 2. Hazard Ratios (95% CIs) Showing the Association Between Changes in CAC and Incident Heart Failure in the Full Cohort
Models (No. of Events/Analyzed) Model 1* (182/5644) Model 2† (168/5384) Model 3‡ (90/5049)
Absolute changes in CAC per year§ 1.05 (1.04–1.06)k 1.02 (1.004–1.04)k 1.03 (1.01–1.05)k
Progressors vs nonprogressors 2.74 (2.05–3.68)k 1.29 (0.93–1.81) 1.25 (0.79–1.97)
*Model 1: unadjusted.
†
Model 2: adjusted for age, sex, race, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), use of antihypertensive medication, total cholesterol, high-density lipoprotein (HDL)
cholesterol, use of lipid-lowering medication, diabetes mellitus, cigarette smoking status, heart rate, creatinine, highest education level, household income, and baseline coronary artery
calcium (CAC) score (Exam 1).
‡
Model 3: Model 2 after excluding participants with any coronary heart diseases.
§
Hazard ratio (HR) per 10 Agatston Unit annual increase in CAC.
k
Statistically significant HRs (95% CIs).
Table 1. Baseline Characteristics of Participants
Characteristics MeanSD or N (%) Characteristics MeanSD or N (%)
All participants 5644 LDL cholesterol, mg/dL 117.331
Males 2662 (47.2) HDL cholesterol, mg/dL 5114.7
Age, y 61.710.2 Lipid-lowering medication 909 (16.1)
Race Diabetes mellitus
White 2232 (39.5) Normal 4209 (74.8)
Black 1529 (27.1) Impaired fasting glucose 764 (13.6)
Hispanic 1207 (21.4) Untreated diabetes mellitus 146 (2.6)
Chinese 676 (12) Treated diabetes mellitus 508 (9)
Highest education level Smoking status
25th percentile Completed high school/GED Never smoker 2868 (51)
Median Some college but no degree Former smoker 2068 (36.7)
75th percentile Bachelor’s degree Current smoker 694 (12.3)
Household income Creatinine, mg/dL 0.950.25
25th percentile $20 000 to $24 999 Heart rate (beats per minute) 639.6
Median $40 000 to $49 999 CAC score=0 2923 (51.8)
75th percentile $50 000 to $74 999 CAC score >0 to 100 1481 (26.2)
BMI, kg/m2 28.35.4 CAC score >100 1240 (22)
SBP, mm Hg 125.721 CAC score (Agatston Unit) in
participants with CAC >0
270.6506
DBP, mm Hg 71.810.2
Blood pressure medication 2023 (35.9%) Interscan period, yr 2.40.9
These figures are numbers (%) and meanSD. CAC indicates coronary artery calcium; DBP, diastolic blood pressure; GED, general education development; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; SBP, systolic blood pressure.
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multivariate analysis. By excluding participants with any CHD,
these associations were no longer significant.
Discussion
Serial CAC measurement has been suggested as a noninva-
sive method to monitor the progression of CAD.11 It has been
proven, in previous studies, that CAC progression is associ-
ated with future CHD and all-cause mortalities.12,13 In this
study, we found CAC progression as a predictor of incident HF
independent of traditional risk factors for HF and baseline
CAC. We also observed that longitudinal increase in CAC is
associated with greater LVESV and LVEDV as measured by
CMR independent of known risk factors for HF and overt CHD.
CAD is the most common underlying cause of HF
especially in the elderly population.23 LV remodeling after
myocardial infarction is a well-described etiology of HF.24 The
necrotic area will be replaced by fibrotic tissue, which is
nonfunctional and less elastic than myocytes.5 Additionally,
ischemia induces activation of neurohormonal cascade,
which, in fact, has a negative impact on the remaining normal
myocardium.6 In addition to this pathway, CAD and ischemia
may play a crucial rule in the pathophysiology of HF without
presenting as a clinically overt CHD.7 In other words, in many
patients, HF is the first presentation of CAD.15 In our study,
we showed that the association of CAC progression and HF
remained statistically significant, even after excluding all
participants with CHD. Our result is in agreement with a few
previous studies that evaluated the association between
baseline CAC and HF.14,15,17
Kalsch et al in the Heinz Nixdorf Recall Study has shown a
significant association between CAC and history of HF in a
univariate cross-sectional analysis.14 This association became
statistically insignificant after adjusting for traditional cardio-
vascular risk factors. The investigators explained this dimin-
ished association by the fact that cardiovascular risk factors
like hypertension can lead to both CAC formation and HF.
Sakuragi et al recently reported the result of a study on 487
Japanese participants free of CAD and HF at enrollment.17
During the mean follow-up of 497315 days, 9 participants
developed incident HF without any overt CHD. Higher CAC
was associated with higher incidence of HF and higher NT-pro
BNP level. The number of incident HFs in this study was
limited and the investigators proposed a multicenter study to
confirm the association of CAC and HF. In another study,
Leening et al investigated the association between baseline
CAC and HF in the Rotterdam study.15 In this population-
based study, 1897 participants free of any history of CHD and
HF were followed for a median of 6.8 years for incident HF
and CHD events. Baseline CAC was strongly associated with
higher incidence of HF independent of traditional cardiovas-
cular risk factors. This association remained statistically
significant after excluding the participants with incident
myocardial infarction or revascularization procedures. This
study was done on a Dutch elderly population, and the result
cannot be extrapolated to the middle-age population and
other ethnic groups.
There are some possible explanations for the association
between CAD and HF in patients without overt CHD. Coronary
artery endothelial dysfunction is an integral part of the
cascade that eventually results in atherosclerotic plaque
formation.25 Dysfunctional endothelium produces more vaso-
constrictors like endothelin instead of vasodilator sub-
stances.26 These vasoconstrictor substances have a direct
detrimental effect on the myocardium, which eventually lead
to myocardial fibrosis and HF.27 In addition, in patients
without clinically overt CHD, chronic ischemia/hypoperfusion
may result in a hibernating myocardium.6 Consequently, in the
affected area, apoptosis may occur, which, in turn, will result
in myocardial dysfunction.28
In the second part of the study, we observed a direct
association between CAC progression and follow-up LVESV
Table 3. Hazard Ratios (95% CIs) Showing the Association Between Changes in CAC and Incident Heart Failure in Participants
With Baseline CAC=0 and Baseline CAC >0 Separately
Models (No. of
Events/Analyzed)
Baseline CAC=0 Baseline CAC >0
Model 1* (49/2923) Model 2† (46/2791) Model 3‡ (33/2741) Model 1* (133/2721) Model 2† (122/2593) Model 3‡ (57/2308)
Absolute changes
in CAC per year§
2.02 (1.47–2.78)k 1.8 (1.21–2.69)k 1.79 (1.08–2.95)k 1.04 (1.03–1.05)k 1.02 (0.999–1.03) 1.02 (1.001–1.05)k
Progressors vs
nonprogressors
3.74 (2.12–6.62)k 2.52 (1.36–4.67)k 2.39 (1.15–4.95)k 1.54 (1.08–2.19)k 1.09 (0.74–1.59) 0.98 (0.56–1.68)
*Model 1: unadjusted.
†
Model 2: adjusted for age, sex, race, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), use of antihypertensive medication, total cholesterol, high-density lipoprotein (HDL)
cholesterol, use of lipid-lowering medication, diabetes mellitus, cigarette smoking status, heart rate, creatinine, highest education level, household income, and baseline coronary artery
calcium (CAC) score (Exam 1).
‡
Model 3: Model 2 after excluding participants with any coronary heart diseases.
§
Hazard ratio (HR) per 10 Agatston Unit annual increase in CAC.
k
Statistically significant HRs (95% CIs).
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and LVEDV, independent of baseline CAC, traditional cardio-
vascular risk factors, and overt CHD. The result of our study is
in line with a few previous studies that investigated the
relationship between subclinical atherosclerosis and LV
dysfunction.29,30 Edvardsen et al studied the relation between
regional CAC and regional LV systolic dysfunction in 509
MESA participants.29 High regional CAC were associated with
regional myocardial dysfunction defined by LV circumferential
strain and strain rate in the same perfusion territory.
However, this study did not show any association between
increased CAC and decrease in SV and EF. In another study,
Colletti et al investigated the association between CAC and
LV dysfunction measured by CMR.30 At enrollment, the
participants of the South Bay Heart Watch (SBHW) were older
than 45 years with various cardiovascular risk factors, but
without any evidence of CHD. CAC was measured in a group
of 1312 SBHW participants. After a mean of 11 years, 386
participants underwent CMR to measure LV function param-
eter, including EF, peak filling rate, and regional wall motion
abnormalities (RWMAs). The association between baseline
CAC and follow-up RWMA remained statistically significant
even after adjusting for cardiovascular risk factors.
The clinical importance of subclinical LV dilatation has
been shown in previous studies.31–33 In a study on partici-
pants of the Framingham Heart Study and Framingham
Offspring Study, 4744 individuals free of myocardial infarction
and HF who underwent echocardiography at baseline were
followed for incident HF.32 It was shown that increased LVED
and LVES dimensions were associated with higher incidence
of future HF. In another study, Yeboah et al demonstrated the
association between LV dilatation measured by CMR at
baseline with incident HF in 4974 MESA participants during
over 9.4 years follow-up.33
In our study, progressors failed to show any statistically
significant increase in incidence of HF or subclinical decrease
in EF and SV in adjusted models. There are some explanations
for this finding. CAC and HF share many common risk factors
like SBP, which behave as confounders in their relation. The
association between CAC and HF is not as strong as the
association between CAC and CHD, and by categorizing
the participants, there is not enough power to detect this
association. Finally, there are many different definitions in the
literature for progressors. Utilizing different methods to define
progressors will cause at least minor discrepancy in the
results.
Strength and Limitations
MESA is a well-designed, multiethnic, population-based study
with long-term follow-up. In addition to the general strength of
MESA, our study is the first to investigate the association of
CAC progression with HF and subclinical LV dysfunction.
There are some limitations that need to be mentioned. MESA
participants were free of any cardiovascular disease at study
entry, and the number of events can be different from general
Figure. Kaplan–Meier curves of cumulative events show higher
rate of incident heart failure in progressors versus nonprogressors
in full cohort (A), in participants free of coronary artery calcium
(CAC) at baseline (B), and in participants with baseline CAC >0
(C). The Kaplan–Meier curves for progressors and nonprogressors
overlap for the first 3 years of follow-up because we only included
the heart failure events that occurred after second CAC
measurement.
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population. The HF event ascertainment in MESA is based on
the data collected from medical records at the time of
diagnosis and therefore is subject to misclassification from
accuracy and performance of the diagnostic tools, such as
echocardiography and clinical data. Nevertheless, this is the
standard method in most of the large-scale, prospective
cohort studies, where the event ascertainment and data
collection on events are often performed after the events
have already occurred.34–36 Additionally, given the unavail-
ability of EF at the time of diagnosis of HF for all participants,
we did not differentiate cases into HF with preserved EF and
HF with reduced EF. For the subclinical assessment of LV,
CMR was available for less than half of the participants.
Although we found a statistically significant association
between longitudinal increase in CAC and LVESV and LVEDV,
the strength of the association is not strong enough to be
meaningfully translated into clinical practice.
Conclusion
In a multiethnic, population-based study, we have shown that
CAC progression predicts incident HF and increased LVEDV
and LVESV measured by CMR at follow-up exam independent
of traditional cardiovascular risk factor, baseline CAC, and
overt CHD. Despite the presence of the statistically significant
association between CAC progression and subclinical LV
dilatation in participants free of any CHD, these weak
associations may not be of any clinical significance. We
recommend further research to identify the subgroup of
individuals who will benefit from serial CAC measurement for
cardiovascular risk stratification.
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Progression and the Left Ventricular Function and Structure Measures by Cardiac Magnetic Resonance in Full Cohort
Models (n) Absolute Changes in CAC Per Year* Progressors vs Nonprogressors
EF Model 1† (2721) 0.04 (0.11 to 0.03) 0.24 (0.88 to 0.41)
Model 2‡ (2598) 0.07 (0.15 to 0.01) 0.01 (0.67 to 0.64)
SV Model 1 (2719) 0.05 (0.04 to 0.14) 0.42 (0.33 to 1.17)
Model 2 (2596) 0.04 (0.06 to 0.13) 0.53 (0.24 to 1.3)
LVEDV Model 1 (2720) 0.14 (0.01 to 0.28) 1.21 (0.02–2.39)§
Model 2 (2597) 0.16 (0.01–0.31)§ 0.98 (0.21–2.18)
LVESV Model 1 (2719) 0.09 (0.002–0.18)§ 0.79 (0.06–1.51)§
Model 2 (2596) 0.12 (0.03–0.21)§ 0.44 (0.26 to 1.15)
LVM Model 1 (2720) 0.08 (0.03 to 0.20) 0.70 (0.31 to 1.70)
Model 2 (2597) 0.1 (0.03 to 0.23) 0.61 (0.42 to 1.64)
MVR Model 1 (2722) 0.001 (0.003 to 0.001) 0.01 (0.02 to 0.01)
Model 2 (2599) 0.001 (0.003 to 0.001) 0.01 (0.02 to 0.01)
CAC indicates coronary artery calcium; EF, ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVM, left ventricular mass; MVR, mass
to volume ratio; SV, stroke volume.
*Coefficient (95% CI) per 10 Agatston Unit annual increase in CAC.
†
Model 1: adjusted for age, sex, race, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), use of antihypertensive medication, total cholesterol, high-density lipoprotein (HDL)
cholesterol, use of lipid-lowering medication, diabetes mellitus, cigarette smoking status, heart rate, creatinine, highest education level, household income, and baseline CAC score (Exam 1).
‡
Model 2: Model 1 after excluding participants with any coronary heart diseases.
§
Statistically significant coefficients (95% CIs).
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SUPPLEMENTAL MATERIAL 
Table S1. Hazard ratio's (95% CIs) showing the association between CAC progression and incident heart failure in 
participants with available measurements of baseline NT-proBNP.   
Models 
(Number of events/analyzed) 
Model 1* 
(142/4664) 
Model 2† 
(135/4497) 
Model 3‡ 
(75/4214) 
Absolute changes in CAC per year§ 1.06 
(1.05-1.07) 
1.02 
(1.003-1.04) 
1.03 
(1.001-1.05) 
Progressors vs. non-progressors 2.68 
(1.92-3.73) 
1.21 
(0.83-1.75) 
1.22 
(0.74-2.03) 
 
Statistically significant HRs (95% CIs) are showed in bold. *Model1: unadjusted. †Model 2: adjusted for age, 
gender, race, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), use of antihypertensive 
medication, total cholesterol, high density lipoprotein (HDL) cholesterol, use of lipid lowering medication, diabetes, 
cigarette smoking status, heart rate, creatinine, highest education level, household income  , baseline CAC 
score and N-terminal prohormone of brain natriuretic peptide (NT-proBNP , all covariates from Exam 1) .‡ 
Model3: Model 3 after excluding participants with any coronary heart diseases. §Hazard ration per 10 U annual 
increase in CAC.   
 
 
 
 
 
 
 
 
 
Table S2. Comparing the parameter of LV function and structure measured by cardiac magnetic resonance in 
participants with baseline CAC=0 and participants with baseline CAC>0 
 
MRI parameter 
at Exam 5 (unit) 
Baseline CAC=0 Baseline CAC>0 P value 
EF (%) 62.2 ± 7.1 61.6 ± 7.4 0.01 
SV (ml/m2) 40.2 ± 8.2 39.1 ± 8.8 0.001 
LVEDV (ml/m2) 64.9 ± 13.1 64.1 ± 14.8 0.1 
LVESV (ml/m2) 24.7 ± 8 24.9 ± 9.1 0.52 
LM (gram/m2) 64.5 ± 13.3 68.1 ± 13.7 <0.001 
MVR (gram/ml) 1 ± 0.2 1.1 ± 0.2 <0.001 
Statistically significant p-values are showed in bold. CAC: coronary artery calcium, EF: ejection fraction; SV: stroke 
volume; LVEDV: left ventricular end diastolic volume; LVESV: left ventricular end systolic volume; LVM: left 
ventricular mass; MVR: mass to volume ration. 
Table S3. Estimated regression coefficients and their 95% confidence intervals showing the association between 
CAC progression and the left ventricular function and structure measures by cardiac MRI in participants with 
baseline CAC=0. 
 
 
 
 
 
 
 
 
 
 
   Statistically significant coefficients (95% CIs) are showed in bold.*Model 1: adjusted for age, sex, race, BMI, 
systolic blood pressure (SBP), diastolic blood pressure (DBP), use of antihypertensive medication, total cholesterol, 
high density lipoprotein (HDL) cholesterol, use of lipid lowering medication, diabetes , cigarette smoking status, 
heart rate, creatinine, highest education level, household income and baseline CAC score (Exam 1).† Model2: 
Model 1 after excluding participants with any coronary heart diseases. ‡Coefficient (95% CI) per 10 Agatston Unit 
annual increase in CAC.  CAC: coronary artery calcium, EF: ejection fraction; SV: stroke volume; LVEDV: left 
ventricular end diastolic volume; LVESV: left ventricular end systolic volume; LVM: left ventricular mass; MVR: 
mass to volume ration. 
 
 Models(n) Absolute changes in CAC 
per year‡ 
Progressors vs.  
non- progressors 
EF Model 1* (1545) -0.48 (-2.04 to 1.08) -0.22 (-1.21 to 0.77) 
Model 2† (1521) -0.38 (-1.96 to 1.18) -0.11 (-1.11 to 0.89) 
SV Model 1 (1544)  1.26 (-0.53 to 3.05) 0.16 (-0.98 to 1.30) 
Model 2 (1520) 0.93 (-0.87 to 2.73) 0.12 (-1.03 to 1.27) 
LVEDV Model 1 (1544) 2.96 (0.21 to 5.70) 0.75 (-0.99 to 2.50) 
Model 2 (1520) 2.22(-0.52 to 4.97) 0.50 (-1.26 to 2.25) 
LVESV Model 1 (1544) 1.7 (0.02 to 3.37) 0.59 (-0.47 to 1.65) 
Model 2 (1520) 1.29 (-0.38 to 2.95) 0.37 (-0.69 to 1.44) 
LVM Model 1 (1544) 2.45 (0.11 to 4.78) 0.77 (-0.71 to 2.25) 
Model 2 (1520) 2.10 (-0.25 to 4.45) 0.75 (-0.74 to 2.25) 
MVR Model 1 (1545) -0.01 (-0.06 to 0.03) 0.01 (-0.02 to 0.04) 
Model 2 (1521) -0.01 (-0.05 to 0.04) 0.01 (-0.02 to 0.04) 
Table S4. Estimated regression coefficients and their 95% confidence intervals showing the association between 
CAC progression and the left ventricular function and structure measures by cardiac MRI in participants with 
baseline CAC>0. 
 
 Models(n) Absolute changes in CAC 
per year‡ 
CAC progression vs.  
no progression 
EF Model 1* (1176) -0.02 (-0.1 to 0.06) -0.32 (-1.19 to 0.54) 
Model 2† (1077) -0.05 (-0.13 to 0.03) 0.01 (-0.87 to 0.89) 
SV Model 1 (1175) 0.05 (-0.05 to 0.15) 0.58 (-0.44 to 1.61) 
Model 2 (1076) 0.04 (-0.06 to 0.15) 0.83 (-0.24 to 1.90) 
LVEDV Model 1 (1176) 0.12 (-0.05 to 0.28) 1.55 (-0.12 to 3.23) 
Model 2 (1077) 0.15 (-0.02 to 0.32) 1.35 (-0.33 to 3.04) 
LVESV Model 1 (1175) 0.07 (-0.03 to 0.17) 0.97 (-0.07 to 2.01) 
Model 2 (1076) 0.11 (0.01 to 0.20) 0.52 (-0.45 to 1.49) 
LVM Model 1 (1176) 0.07 (-0.06 to 0.21) 0.68 (-0.72 to 2.09) 
Model 2 (1077) 0.09 (-0.06 to 0.23) 0.56 (-0.91 to 2.04) 
MVR Model 1 (1177) -0.001 (-0.003 to 0.001) -0.01 (-0.04 to 0.01) 
Model 2 (1078) -0.001 (-0.003 to 0.001) -0.01 (-0.04 to 0.01) 
Statistically significant coefficients (95% CIs) are showed in bold. *Model 1: adjusted for age, sex, race, BMI, 
systolic blood pressure (SBP), diastolic blood pressure (DBP), use of antihypertensive medication, total cholesterol, 
high density lipoprotein (HDL) cholesterol, use of lipid lowering medication, diabetes, cigarette smoking status, 
heart rate, creatinine, highest education level, household income and baseline CAC score (Exam 1). † Model2: 
Model 1 after excluding participants with any coronary heart diseases. ‡Coefficient (95% CI) per 10 Agatston Unit 
annual increase in CAC. CAC: coronary artery calcium, EF: ejection fraction; SV: stroke volume; LVEDV: left 
ventricular end diastolic volume; LVESV: left ventricular end systolic volume; LVM: left ventricular mass; MVR: 
mass to volume ration.  
